Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Profound Medical (PROF) EBIT (2023 - 2025)

Historic EBIT for Profound Medical (PROF) over the last 3 years, with Q3 2025 value amounting to -$8.9 million.

  • Profound Medical's EBIT rose 94.47% to -$8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.2 million, marking a year-over-year increase of 4231.03%. This contributed to the annual value of -$33.1 million for FY2024, which is 1539.56% down from last year.
  • According to the latest figures from Q3 2025, Profound Medical's EBIT is -$8.9 million, which was up 94.47% from -$13.8 million recorded in Q2 2025.
  • In the past 5 years, Profound Medical's EBIT ranged from a high of $6.8 million in Q1 2023 and a low of -$48.5 million during Q4 2023
  • Its 3-year average for EBIT is -$8.7 million, with a median of -$8.3 million in 2024.
  • Examining YoY changes over the last 5 years, Profound Medical's EBIT showed a top increase of 8278.85% in 2024 and a maximum decrease of 23716.46% in 2024.
  • Over the past 3 years, Profound Medical's EBIT (Quarter) stood at -$48.5 million in 2023, then surged by 82.79% to -$8.3 million in 2024, then decreased by 6.81% to -$8.9 million in 2025.
  • Its last three reported values are -$8.9 million in Q3 2025, -$13.8 million for Q2 2025, and -$11.2 million during Q1 2025.